Skip to content

TALUS BIOSCIENCE, INC.

Seattle, WA

Oncologysmall moleculeGrant-only

What changed

NIH R44 · $0.8M · Activity-based regulome profiling for the discovery of covalent transcription factor inhibitors

Jan 2025Grant renewalJan 16, 2025Source filing (opens the source filing in a new tab)

Momentum

14no change

Momentum 14 out of 100, unchanged since the last recompute.

Little recent filing activity, or the events on file have decayed.

Runway (estimate)

unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources